Original images vs. portraits on canvas: 'An artist's model in the camera lens'Society & Culture March 30, 17:24
Putin thanks CNBC anchor for correctly setting Crimea apart from UkraineRussian Politics & Diplomacy March 30, 16:57
Putin says no plans to restrict rocket engine supplies to USScience & Space March 30, 16:49
Russia’s Space Force deploys high-tech space monitoring systemsMilitary & Defense March 30, 16:25
Putin stresses Russia’s military activities in Arctic threaten no oneRussian Politics & Diplomacy March 30, 16:18
Russia and Norway team up to clean Arctic of nuclear wasteWorld March 30, 16:10
Putin: Corruption must be fought against, but using this issue to score points is wrongRussian Politics & Diplomacy March 30, 16:07
Putin blasts 'worthless' allegations of 'Russian aggressiveness'Russian Politics & Diplomacy March 30, 15:57
Putin comments on recent protests across RussiaRussian Politics & Diplomacy March 30, 15:49
MOSCOW, April 14 (Itar-Tass) —— The Russian Skolkovo innovation centre’s resident company is developing innovative medicines against AIDS.
“These medicines use an absolutely new mechanism of action. Molecules affect structural protein that is critical for the HIV virus,” Quantum Pharmaceuticals Deputy Director Maxim Kholin said in an exclusive interview with Itar-Tass.
“The mechanism of action has its peculiarities and they allow us to expect our medicines to be less toxic for the human organism than many others now available. This is very important because the development of medicines against HIV is facing two problems: the virus is highly variable and medicines are toxic,” Kholin noted.
“We are continuing research and getting good results,” he added.
“Skolkovo has supported our project and helped us move forward considerably. It’s important to say that the substances have been developed using our own molecular modelling technology, one of the leading technologies in the world. We also actively use this technological platform for developing other antiviral medicines, new cancer medications and antibiotics. We work both on our own and in partnership with leading international research centres,” Kholin said.